Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma-Reference-Cited by-同舟云学术

Potent antitumor effects of combined therapy with a telomerase-specific, replication-competent adenovirus (OBP-301) and IL-2 in a mouse model of renal cell carcinoma

Published:2010-02-19 Issue:7 Volume:17 Page:484-491
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Huang P,Kaku H,Chen J,Kashiwakura Y,Saika T,Nasu Y,Urata Y,Fujiwara T,Watanabe M,Kumon H

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/cgt20105.pdf

Reference18 articles.

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ . Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43–66.

2. Blackburn EH . Structure and function of telomeres. Nature 1991; 350: 569–573.

3. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011–2015.

4. Shay JW, Wright WE . Telomerase activity in human cancer. Curr Opin Oncol 1996; 8: 66–71.

5. Nakayama J, Tahara H, Tahara E, Saito M, Ito K, Nakamura H et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998; 18: 65–68.

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An oncolytic virus as a promising candidate for the treatment of radioresistant oral squamous cell carcinoma;Molecular Therapy - Oncolytics;2022-12

2. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy;Frontiers in Microbiology;2021-07-21

3. Development of oncolytic virotherapy: from genetic modification to combination therapy;Frontiers of Medicine;2020-03-07

4. Advances in delivery vectors for gene therapy in liver cancer;Therapeutic Delivery;2020-01

5. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives;Japanese Journal of Clinical Oncology;2018-11-20